Guardion Health Sciences (STU:0QTA) EBIT : €-3.66 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Guardion Health Sciences EBIT?

Guardion Health Sciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was €-0.64 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Guardion Health Sciences's annualized ROC % for the quarter that ended in Dec. 2023 was -68.31%. Guardion Health Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -68.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Guardion Health Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -82.81%.

Guardion Health Sciences EBIT Historical Data

The historical data trend for Guardion Health Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences EBIT Chart

Guardion Health Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-9.56

-7.04

-9.28

-6.91

-3.62

Guardion Health Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-1.21	-1.37	-0.94	-0.72	-0.64

Competitive Comparison of Guardion Health Sciences's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardion Health Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's EV-to-EBIT falls into.

Guardion Health Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.66 Mil.

Guardion Health Sciences (STU:0QTA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Guardion Health Sciences's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-2.54 * ( 1 - 0% )	/	( (3.55	+	3.887)	/ 2 )
=	-2.54	/	3.7185
=	-68.31 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12.067	-	1.342	-	( 7.175	-	max(0, 1.342	-	12.031	+	7.175	))
=	3.55

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.929	-	1.21	-	( 5.832	-	max(0, 1.21	-	10.899	+	5.832	))
=	3.887

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Guardion Health Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.54	/	( ( (0.036 + max(3.514, 0))	+	(0.03 + max(3.857, 0)) )	/	2 )
=	-2.54	/	( ( 3.55	+	3.887 )	/	2 )
=	-2.54	/	3.7185
=	-68.31 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.655	+	2.297	+	0.904)	-	(1.342	+	0	+	0)
=	3.514

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.085	+	2.455	+	0.527)	-	(1.21	+	0	+	0)
=	3.857

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Guardion Health Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-3.661	/	4.421
	=	-82.81 %

Guardion Health Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardion Health Sciences (STU:0QTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (STU:0QTA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

GHSI:USA

Address

2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098

Website

https://www.guardionhealth.com

Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.

Guardion Health Sciences (STU:0QTA) Headlines

No Headlines